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The First Case of Catheter-related Bloodstream Infection Caused 
by Nocardia farcinica 
Nocardia farcinica is an emerging pathogen in immunocompromised hosts. Even though 
several species of Nocardia have been reported as causative pathogens of catheter-related 
blood stream infections (CRBSI), CRBSI caused by N. farcinica has not been reported. A 
70-yr-old man with a tunneled central venous catheter (CVC) for home parenteral nutrition 
was admitted with fever for two days. Norcardia species was isolated from the blood 
through CVC and peripheral bloods and identified to N. farcinica by 16S rRNA and rpoB 
gene sequence analyses. This report emphasizes the rapid and correct identification of 
causative agents in infectious diseases in the selection of antimicrobial agents and the 
consideration of catheter removal.
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INTRODUCTION
More than 70 taxonomical species have been recognized in the 
genus Nocardia. Of these, N. asteroides, N. nova, N. cavie, N. far-
cinica, N. brasiliensis, N. pseudobrasiliensis, N. otitidiscaviarum 
and N. transvalensis are known to cause infections in human. 
Predisposing conditions of Nocardia infection include solid tu-
mors, hematologic malignancies, treatment with corticosteroids, 
bone marrow or solid organ transplantation, chronic pulmonary 
or renal diseases and acquired immunodeficiency syndrome (1). 
  Nocardia farcinica has been increasingly recognized as a caus-
ative microorganism of human infections (2). Unlikely other 
Nocardia spp., N. farcinica is characteristically resistant to mul-
tiple antimicrobial agents, including third-generation cephalo-
sporins (3). Consequently, a patient who is infected by N. farci-
nica faces difficulty in treatment and the outcome is often death. 
Fortunately, N. farcinica rarely causes serious infections in im-
munocompetent hosts (1). Catheter-related bloodstream infec-
tion (CRBSI) caused by N. farcinica has not been reported to 
date. In this paper, we report the first case of CRBSI caused by 
N. farcinica, which was identified using 16S rRNA and rpoB 
gene sequences. 
 
CASE REPORT
A 70-yr-old man with a two days history of fever was admitted 
to the Samsung Medical Center (SMC) in March 2005. The pa-
tient had been treated for atrial fibrillation and hypertension for Heo ST, et al.  •  N. farcinica Catheter-related Bloodstream Infection
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the past several years. Two months previously, the patient had 
undergone an ileojejunal resection and right-sided hemicolec-
tomy because of acute mesenteric infarction. Thereafter, the 
patient had been receiving home parenteral nutrition via a tun-
neled central venous catheter (CVC; Hickman catheter). The 
patient had no history of travel or contact with animals. Physical 
examination revealed a body temperature of 38.8°C. The right 
subclavian tunneled CVC displayed erythema and minimal pu-
rulent discharge at the exit site. Laboratory data including com-
plete blood counts and blood chemistry were within normal 
limits and a chest radiograph was unremarkable. Three sets of 
blood samples for culture were drawn through the CVC (two 
sets) and a peripheral vein (one set). The patient was empirical-
ly treated with cefazolin (1 g every 8 hr intravenously). Later, cip-
rofloxacin (200 mg every 12 hr intravenously) was added to cov-
er gram-negative rods. On day 5 of hospitalization, all the blood 
cultures yielded gram-positive rods. The bacteria grew at least  
2 hr earlier in blood obtained from the CVC than blood obtained 
from the vein. By day 8, the bacteria had been identified as No-
cardia species as described below. Cefazolin and ciprofloxacin 
were empirically substituted by parenteral trimethoprim-sulfa-
methoxazole (TMP-SMX, 15 mg/kg/day of trimethoprim) em-
pirically after the identification of Nocardia spp. The CVC was 
removed because of persistent fever. Thereafter, the patient be-
came afebrile and repeated blood cultures were negative. On 
day 17, the patient was switched from parenteral to oral TMP-
SMX. Oral TMP-SMX was continued for 6 weeks. At a 3-month 
follow-up after discontinuation of TMP-SMX, the patient was 
well with no evidence of recurrence. 
  In vitro susceptibility testing was performed by broth micro-
dilution method as described by the Clinical and Laboratory 
Standards Institute (CLSI) guidelines (4). The results are shown 
in Table 1. Conventional automated methods such as the VITEK 
II system (bioMerieux, Hazelwood, MO) were unable to identi-
fy this isolate [“SMC-A7077”] to a given Nocardia species. Thus, 
16S rRNA and rpoB gene sequence analyses were performed by 
using primer sets of 16S-F3 (5´-CAG GCC TAA CAC ATG CAA 
GT-3´)/16S-R3 (3´-GGG CGG WGT GTA CAA GGC-3´) and MF 
(5’-CGA CCA CTT CGG CAA CCG-3´)/MR (5´-TCG ATC GGG 
CAC ATC CGG-3´), respectively (5). DNA was amplified by poly-
merase chain reaction (PCR). Purification of the PCR product 
and sequencing were also performed as previously described. 
Determined sequences were compared with the public data-
bases EzTaxon (http://www.eztaxon.org) and GenBank (http://
www.ncbi.nlm.nih.gov/blast) using blast searches. 
  The 16S rRNA gene sequence (1,248 bp) of the isolate showed 
the greatest similarity (99.92%) to N. farcinica ATCC 3318
T [Gen-
Bank no. Z36936], followed by N. higoensis IFM 10084
T (98.80%), 
N. shimofusensis IFM 10311
T (98.72%) and N. asiatica IFM 0245
T 
(98.72%). The rpoB gene sequence (296 bp) of isolate SMC-A7077 
showed complete identity with those of several N. farcinica stra-
ins such as DSM 43578, IFM 0284 and IFM 10152. However, it 
showed similarity values of 96.59% with N. shimofusensis DSM 
44733
T, 95.56% with N. vaccinii CIP 1775.88
T, and 95.22% with N. 
higoensis DSM 44732
T. The phylogenetic relationships of isolate 
SMC-A7077 with other related Nocardia strains based on rpoB 
gene sequences are shown in Fig. 1. Based on 16S rRNA and 
rpoB gene sequence analyses, we concluded that the isolate 
SMC-A7077 was N. farcinica. 
 
DISCUSSION
Species identification among Nocardia spp. is important to select 
appropriate antimicrobial agents because antimicrobial resis-
tance profiles are different among Nocardia spp. For the identi-
fication of unidentified bacteria or isolates with ambiguous pro-
files, 16S rRNA gene sequences have been used. Although there 
Table 1. Results of antimicrobial susceptibility testing for isolate SMC-A7077
Antimicrobials
Minimum inhibitory 
concentration (MIC) (mg/L)
Susceptibility*
Ceftriaxone   8 S
Cefotaxime   4 S
Amikacin      0.5 S
Gentamicin 64 R
Imipenem   1 S
Ciprofloxacin   4 R
Ampicillin >64 NA
Erythromycin 32 NA
Trimethoprim-sulfamethoxazole 0.25/4.75 S
Vancomycin >64 R
*S, susceptible; R, resistant.
NA, not available. 
N. farcinica DSM 43578
N. farcinica IFM 0284
N. farcinica IFM 10152
A7077
N. vaccinii CIP1775.88
N. inohanensis DSM 44667
N. yamanashiensis DSM 44669
N. crassostreae ATCC 700418
N. transvalensis CIP 1574.88
N. shimofusensis DSM 44833
N. higoensis DSM 44732
N. novocastrense CIP 105546
N. farcinogenes DSM 43637
N. puris DSM 44599
N. pneumoniae DSM 44730
N. araoensis DSM 44729
67
77
69
72
58
98
100
M. tuberculosis H37Ra
0.01
Fig. 1. Phylogenetic tree of SMC-A7077 and closely related species of Nocardia based 
on partial rpoB gene sequences. The tree was reconstructed by the neighbor-joining 
method, and Mycobacterium tuberculosis H37Ra was used as an outgroup. Numbers 
on branching nodes are percentages of 1,000 bootstrap replications. Only values of 
≥50% are shown. The scale bar represents one substitution per 100 nucleotides. Heo ST, et al.  •  N. farcinica Catheter-related Bloodstream Infection
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are no universal criteria for species identification definition, iso-
lates with sequence identity >99% are generally considered to 
belong to the same species (6). However, 16S rRNA gene is inap-
propriate for some genera including Nocardia due to high simi-
larity. Other more variable housekeeping genes such as rpoB 
and gyrB have been suggested for alternate targets of bacterial 
identification (5). 
  Most CRBSIs emanate from the insertion site and skin is a 
prominent source of microbes causing bloodstream infection. 
The microbes that most commonly cause CRBSI associated with 
percutaneously inserted catheters are coagulase-negative staph-
ylococci, S. aureus, Candida species, and enteric gram-negative 
bacilli (7). While N. asteroides, N. nova and N. cavie have been 
rarely associated with CRBSI in immunocompromised hosts, 
CRBSI caused by N. farcinica has not been reported (7-11). Al-
though brain or intramuscular abscess, pneumonia or osteomy-
elitis by N. farcinica have been reported worldwide including 
Korea (12-16), bacteremic infection due to N. farcinica related 
with catheters has not been reported to our knowledge. In this 
report, we describe for the first time CRBSI caused by N. farci-
nica. 
  N. farcinica is increasingly recognized as a human pathogen 
in infections of the lung, brain, skin, wounds and kidney (12). 
Resistance to antimicrobial agents occurs more frequently in N. 
farcinica than in other Nocardia spp. N. farcinica is usually sus-
ceptible to TMP-SMX, amikacin, imipenem and ciprofloxacin, 
but is often resistant to third-generation cephalosporin, ampicil-
lin, erythromycin and gentamicin. TMP-SMX has been selected 
as the first choice for the treatment in patients with infections 
by Nocardia spp. N. farcinica strains resistant to multiple anti-
biotics including TMP-SMX have been recently reported (3). 
Considering the possibility of TMP-SMX resistance, some au-
thors have proposed amikacin in combination with imipenem 
or amoxicillin-clavulanate as the first-line therapy (9, 12). Fluo-
roquinolones have emerged as one of the potentially attractive 
candidates for the treatment of infections by N. farcinica (17). In 
some reports, infections caused by multidrug-resistant N. farci-
nica in immunocompromized hosts were successfully treated 
with linezolid (2, 16, 18). 
  Identification of clinical isolates using conventional automat-
ed methods usually is reported as the genus Nocardia (‘Nocar-
dia species’), rather than to the species level. Given the afore-
mentioned antibiotic resistance concerns posed by N. farcinica, 
it is prudent to suggest that molecular identification or antimi-
crobial susceptibility test for Nocardia species should be per-
formed when ‘Nocardia species’ is isolated from a specimen cul-
ture to ensure proper treatment. Appropriate duration of anti-
microbial treatment in patients with Nocardia CRBSI is unclear. 
Often, antimicrobial therapy is continued for several months 
after apparent cure because of a concern of high relapse rates of 
nocardiosis. While it has been suggested that pulmonary or sys-
temic nocardiosis in immunocompromized hosts should be 
treated for 6–12 months (12), another report suggested that pro-
longed antibiotics may not be necessary in nocardial CRBSI with-
out distant metastatic infection after removal of catheter (8). 
Presently, the patient was successfully treated with parenteral 
TMP-SMX for 10 days and a subsequent 6-week course of oral 
formulation after removal of the CVC. 
  Specific recommendations for catheter removal in nocardial 
CRBSI have not been forthcoming. A report suggested that no-
cardial bacteremia can be successfully treated without remov-
ing vascular catheters (11), while other case was relapsed after 
management of keeping CVC (19). Three cases were treated with 
removal of CVC (10, 20). In this report, the patient became afe-
brile after CVC removal and administration of parenteral TMP-
SMX. Removal of the catheter is not absolutely indicated but 
should be seriously considered prompt removal of catheter when 
a patient with CRBSI caused by Nocardia species does not re-
spond to appropriate antimicrobial agent(s).
  The present novel report of CRBSI caused by N. farcinica in-
dicates that N. farcinica should be included as a causative mi-
croorganism of CRBSI. Molecular identification for Nocardia 
species as well as antimicrobial susceptibility test will be help-
ful for proper treatment with antimicrobials because antimicro-
bial susceptibility patterns are variable between Nocardia spp.
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